Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib

M. Mian, N. Pescosta, S. Badiali, P.C. Cappelletto, L. Marcheselli, S. Luminari, F. Patriarca, R. Zambello, A. Pascarella, G. Tagariello, A. Marabese, P. Mondello, A. Billio, S. Cortelazzo

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)944-947
Number of pages4
JournalBritish Journal of Haematology
Volume185
Issue number5
DOIs
Publication statusPublished - 2019

Cite this

Mian, M., Pescosta, N., Badiali, S., Cappelletto, P. C., Marcheselli, L., Luminari, S., Patriarca, F., Zambello, R., Pascarella, A., Tagariello, G., Marabese, A., Mondello, P., Billio, A., & Cortelazzo, S. (2019). Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. British Journal of Haematology, 185(5), 944-947. https://doi.org/10.1111/bjh.15645